TRVI Quick Ratio | Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. Quick Ratio

The quick ratio is a stricter test of whether a company can pay the bills due within a year, counting only assets that are already cash or close to it. It is cash, marketable securities and receivables divided by current liabilities, shown as a multiple, with both amounts in the table. It is the current ratio with inventory and other assets that take longer to turn into cash removed, so it is never higher than the current ratio. A company that does not report one of the inputs has no point for that date rather than an estimated one. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.

Trevi Therapeutics, Inc. quick ratio for the quarter ending 2026-06-30 was 36.5, a 65.44% increase year-over-year.
Trevi Therapeutics, Inc. quick ratio for the quarter ending 2026-03-31 was 24.14, a 60.54% increase year-over-year.
Trevi Therapeutics, Inc. quick ratio for the quarter ending 2025-12-31 was 19.31, a 88.56% increase year-over-year.
Trevi Therapeutics, Inc. quick ratio for the quarter ending 2025-09-30 was 21.56, a 200.33% increase year-over-year.
Trevi Therapeutics, Inc. quick ratio for fiscal 2025 was 19.31, a 88.56% increase from fiscal 2024.
Trevi Therapeutics, Inc. quick ratio for fiscal 2024 was 10.24, a 28.12% decline from fiscal 2023.
Trevi Therapeutics, Inc. quick ratio for fiscal 2023 was 14.25, a 58.41% increase from fiscal 2022.
Trevi Therapeutics, Inc. quick ratio for fiscal 2022 was 8.99, a 210.70% increase from fiscal 2021.

Available history: 2018-12-31 to 2026-06-30
Data captured: 2026-06-30

Historical Quick Ratio

Date	Quick Ratio	Quick assets	Current liabilities
2026-06-30	36.5	$318.87M	$8.74M
2026-03-31	24.14	$171.78M	$7.12M
2025-12-31	19.31	$188.26M	$9.75M
2025-09-30	21.56	$194.93M	$9.04M
2025-06-30	22.06	$203.89M	$9.24M
2025-03-31	15.04	$103.26M	$6.87M
2024-12-31	10.24	$107.62M	$10.51M
2024-09-30	7.18	$65.49M	$9.12M
2024-06-30	10.29	$69.5M	$6.75M
2024-03-31	13.8	$72.82M	$5.28M
2023-12-31	14.25	$82.97M	$5.82M
2023-09-30	17.18	$88.87M	$5.17M
2023-06-30	19.99	$94.15M	$4.71M
2023-03-31	8.43	$111.26M	$13.2M
2022-12-31	8.99	$120.51M	$13.4M
2022-09-30	8.58	$125.6M	$14.64M
2022-06-30	5.04	$77.86M	$15.43M
2022-03-31	2.26	$29.11M	$12.87M
2021-12-31	2.89	$36.83M	$12.72M
2021-09-30	2.96	$29.32M	$9.91M
2021-06-30	3.87	$36.43M	$9.41M
2021-03-31	7.79	$41.57M	$5.34M
2020-12-31	8.1	$45M	$5.56M
2020-09-30	8.73	$53.29M	$6.1M
2020-06-30	6.53	$44.18M	$6.77M
2020-03-31	7.31	$52.64M	$7.21M
2019-12-31	11.02	$57.31M	$5.2M
2019-09-30	12.63	$63.52M	$5.03M
2019-06-30	10.05	$71.39M	$7.11M
2019-03-31	3.53	$12.95M	$3.67M
2018-12-31	2.69	$7.2M	$2.68M

Annual Quick Ratio

Date	Quick Ratio	Quick assets	Current liabilities
2025-12-31	19.31	$188.26M	$9.75M
2024-12-31	10.24	$107.62M	$10.51M
2023-12-31	14.25	$82.97M	$5.82M
2022-12-31	8.99	$120.51M	$13.4M
2021-12-31	2.89	$36.83M	$12.72M
2020-12-31	8.1	$45M	$5.56M
2019-12-31	11.02	$57.31M	$5.2M
2018-12-31	2.69	$7.2M	$2.68M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
PALVELLA THERAPEUTICS, INC. (PVLA)	United States	$2.105B	-35.55
Braveheart Bio, Inc. (BRVE)	United States	$2.106B
Bausch Health Companies Inc. (BHC)		$2.113B	-1.68
Generate Biomedicines, Inc. (GENB)	United States	$2.052B
PERRIGO Co plc (PRGO)	Ireland	$2.038B	-0.79
NEKTAR THERAPEUTICS (NKTR)	United States	$2.026B	-9.05
OCULAR THERAPEUTIX, INC (OCUL)	United States	$2.159B	-7.15
Prestige Consumer Healthcare Inc. (PBH)	United States	$2.163B	13.03
UroGen Pharma Ltd. (URGN)		$2.015B	-18.42
Nuvation Bio Inc. (NUVB)	United States	$2.007B	-13.12